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Abstract
Background Codex documents may be used as educa-
tional and consensus materials for member governments.
Also, the WTO SPS Agreement recognizes Codex as the
presumptive international authority on food issues. Nutri-
ent bioavailability is a critical factor in determining the
ability of nutrients to provide beneﬁcial effects. Bioavail-
ability also inﬂuences the quantitative dietary requirements
that are the basis of nutrient intake recommendations and
NRVs.
Health claims Codex, EFSA and some national regula-
tory authorities have established guidelines or regulations
that will permit several types of health claims. The scien-
tiﬁc basis for claims has been established by the US FDA
and EFSA, but not yet by Codex. Evidence-based nutrition
differs from evidence-based medicine, but the differences
are only recently gaining recognition. Health claims on
foods may provide useful information to consumers, but
many will interpret the information to mean that they can
rely upon the food or nutrient to eliminate a disease risk.
Nutrient reference values NRVs are designed to provide
a quantitative basis for comparing the nutritive values of
foods, helping to illustrate how speciﬁc foods ﬁt into the
overall diet. The INL-98 and the mean of adult male and
female values provide NRVs that are sufﬁcient when used
as targets for individual intakes by most adults.
World Trade Organization agreements WTO recognizes
Codex as the primary international authority on food
issues. Current regulatory schemes based on recommended
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Introduction
A previous workshop [1] had reviewed the development
of the Codex Alimentarius (Codex) and its central role in
protecting the health of consumers and ensuring fair
practices in international food trade. This workshop fur-
ther reviewed how Codex promotes harmonization and
consensus by promoting the coordination of Food Stan-
dards established by governments and non-governmental
organizations. Thus, although it has no statutory authority,
it is the guardian of the culture and of the responsible and
objective application of the best available science to risk
analysis and other issues relating to food. Codex docu-
ments have important roles as templates for national
regulations, or as the basis for international trade agree-
ments, and they have a distinctive authority and credi-
bility that is derived from their painstaking development
of a consensus in a multistep procedure that may take
many years. Nevertheless, although this process may
delay the ﬁnal adoption of the document, it provides a
basis for subsequent cooperation after its implementation.
Codex standards are applied in conjunction with the
various agreements—sanitary and phytosanitary (SPS)
agreement and technical barriers to trade (TBT) agree-
ment––adopted as part of the rules of the World Trade
Organisation (WTO). The SPS agreement in particular
requires the use of risk assessment as a component of the
overall risk analysis. The risk analysis itself is intended to
be congruent with the WTO agreements, but certain ele-
ments of risk management and communication may entail
some contextualization according to diverse cultures and
socio-economic situations. The latter may lead to dis-
crepancies in practice and policy leading to disputes
which need WTO arbitration. The fundamental risk
assessment and its quality, whether it is performed within
Codex or elsewhere, is crucial to this process. Thus, in the
widest context, Codex documents have been helpful to
member governments, industry and consumers. An
important outcome is that the documents have been used
in the past 20 years to promote coordination of approa-
ches to setting dietary and nutrient reference values,
standardization of nutrient and health claims and a sys-
tematic approach to nutrient risk assessment and the set-
ting of upper levels of intake or exposure.
Nutritional science, causal inference and health claims
These developments both individually, and overall, dem-
onstrated a need for an appropriate focus of developments
in nutritional research, and in particular, the expected
introduction of health claims was anticipated by what could
be seen as a renaissance of food science. The European
Union and International Life Sciences Institute—Europe
(ILSI-Europe) coordinated Concerted Action, ‘‘Functional
food science in Europe’’ (FUFOSE), re-emphasized the
importance in nutritional science of understanding the
sequential relationship between initial exposure to dietary
component, usually a nutrient, in its dietary matrix, the
intestine uptake and transfer of the nutrient and/or its
metabolites to the body, the subsequent intermediate
metabolism of fate of the component itself, and their ulti-
mate effect on organ or tissue architecture and function
including, with particular relevance to health claims to
improved physiological, or behavioural function, or a
reduced risk of disease [2]. FUFOSE illustrated how this
mechanistic schema could be explored to demonstrate
evidence of causality based on the use of good quality-
assured science and validated markers that demonstrated
the strength of causal inference in the individual steps of
the chain, and the chain overall.
An important uncertainty in this chain is the efﬁciency
with which the dietary component is utilized systemically,
that is, the component’s bioavailability. Evidently, there is
a need to relate the systemic outcome to the initial expo-
sure and internal body burden if one is going to use that
information to develop reference values, or to develop a
case justifying a health claim, or a safe upper limit of
intake. Bioavailability is therefore not just an important
concept in nutritional science, but also, an important value.
However, to say the least, it is difﬁcult to measure,
although many approaches have been used in an attempt to
do so. Most of these do not measure bioavailability
according to the above deﬁnition–probably the incorpora-
tion of iron into haemoglobin is the best example of the few
outcomes that actually measure ‘‘bioavailability.’’ Other-
wise, the various and diverse methods which have been
used to measure bioavailability measure different variants
of true or net intestinal or mucosal uptake and transfer of a
nutrient and do not consider the further systemic metabo-
lism, excretion and utilization of the dietary component.
Furthermore, what is often measured and called bioavail-
ability focuses on the characteristics of the component and
of the dietary matrix as they affect the intestinal uptake and
transfer of the component to the neglect of host factors
which set the intestinal mucosa for the absorption of the
component in question. As such, the term ‘‘bioavailability’’
has more often than not been applied to some aspect of
absorption in such a way as to suit the experimental design
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nutritional science. This uncritical use of ‘‘bioavailability’’
has no value in objective nutritional risk assessment and
cannot be expected to withstand forensic examination. In
fact, to accommodate the complete concept of bioavail-
ability, it is arguable that the term has become devalued
and an impediment to transparent and objective assessment
of dietary nutritional and risk assessment. A potentially
more rewarding approach would be to adopt from nutri-
tion’s sister disciplines of pharmacology and toxicology
the analysis of systemic metabolism of a component with
the Absorption, Distribution, Metabolism, Excretion
(ADME) model. This would provide the basic dose–
response data relevant to intake and metabolism of a die-
tary component and its subsequent effects on the host;
should the appropriate data not exist, then it would enable a
clear exposition of the relevant uncertainties in the nutri-
tional and risk assessment of a dietary component.
The components of an ADME schema ﬁt well with the
mechanistic schema envisaged by FUFOSE as a means of
addressing the functionality of foods or food components
and assessing the evidence available which could be
appraised against the FUFOSE construct. ‘‘Health claims’’
relate to what a food or food constituent does in relation to
nutritional or physiological beneﬁcial effects such as con-
tributions to health maintenance, health improvements and
disease risk reduction. Consumers should be able to make
informed choices based on clear and accurate information
and to have conﬁdence in the scientiﬁc and regulatory
processes used to support claims. Many of the recent and
ongoing developments on the scientiﬁc substantiation of
health claims with particular reference to approaches come
from activities of Codex, the European food safety
authority (EFSA) and the US Food and Drug Administra-
tion (US FDA). These authorities have developed and
adopted methodologies for the assessment of the totality of
the available data and for a suitable framework for
weighing the evidence to reﬂect state-of-the-art nutrition
science, to promote future research and to determine the
extent to which a causal relationship can be demonstrated.
In these approaches, scientiﬁc assessments need to be
proportionate to meet the legitimate expectations of
researchers and applicants for the authorization of a health
claim, and there is a need to link the totality of the avail-
able data and the strength, consistency and biological
plausibility of evidence to claims that are truthful and
meaningful to consumers. In the European context, another
ILSI-Europe hosted Concerted Action the Process for the
Assessment of Scientiﬁc Support for Claims on Foods
(PASSCLAIM) [3] addressed the strategic presentation and
integration of all the evidence relevant to, including that
which might limit a claim, supporting causality. It placed
no particular emphasis or hierarchical precedence of the
types of evidence used but rather emphasized the expec-
tation that the integrity and coherence of the evidence
should be assessed on a case-by-case basis by appropriately
competent assessors and that these assessments would be
accompanied by an exposition of any uncertainties which
might limit conﬁdence in any claimed causal inference.
The expectations and analyses of evidence relevant to
claims have become conditioned by the expectations of
evidence-based approaches. The underpinning assumption
being that evidence-based medicine (EBM) represents the
use of current best evidence in making decisions about
clinical care and that randomized controlled trials (RCTs),
systematic reviews and meta-analyses of such trials are
best practice, and there is little need, therefore, to heed
other forms of evidence such as cohort studies or expert
opinion. Somewhat paradoxically, therefore, clinical rec-
ommendations and guidelines are most frequently made by
expert committees who themselves evaluate the evidence.
Interestingly, evaluation of RCTs versus observational
studies shows they produce very similar ﬁndings overall
[4]. The gold-standard RCT is difﬁcult to apply to nutrition
for several reasons. It is practically impossible to create a
‘‘study nutrient free’’ placebo group. While drugs often
have a single target, nutrition most often has multiple tar-
gets. Effect size for nutrition may be small, but across
multiple systems. However, small effects can be very
important at the population level. Dose–response relation-
ships between nutrient intake and outcome are often non-
linear and may be different for different outcomes. There
may be interactions (additive, synergistic, antagonistic)
with other nutrients or with drugs. Failure to recognize
these features may explain the failure of some nutrition
RCTs and wrong conclusions and judgements can be made
as a result. Systematic reviews and meta-analyses are
increasingly being applied to nutrition and, being based
mainly upon RCT evidence, can suffer from the same
confounding features. The earliest detailed descriptions of
EBM recognized that observational data and expert judg-
ment are essential parts of the EBM decision-making
process [5] and appreciated that RCTs were developed to
compensate the lack of information and quality assurance
about underpinning mechanisms and the difﬁculty to
muster sufﬁcient information to enable an adequate
appraisal by the Hill principles [6]. The crucial element in
this context is the competency and appropriate knowledge
of those who review and assess evidence. It is important
that systematic reviews be conducted by persons with
expertise in the subject being reviewed. The setting of
dietary and nutrient guidelines and recommendations has
typically (and rightly) valued expert opinion, and often
cohort studies have been considered as providing evidence
of at least equal import to that of RCTs. It is clear that,
although the philosophy to use the best quality evidence is
Eur J Nutr (2012) 51 (Suppl 1):S1–S7 S3
123shared between ‘‘medicine’’ and ‘‘nutrition,’’ the approach
used to evaluating the totality of the relevant evidence
needs to be different. As used to support policy and to
satisfy regulatory requirements, evidence-based nutrition
(EBN) and EBM are different. However, the improving
mechanistic insights available through modern cell biology
and its integration into systemic physiology has opened up
opportunities for the more extensive use of mechanistic and
metabolic markers relevant to assessing in an exposure-
related fashion the functional and toxic effects of food
components; this is congruent with the FUFOSE mecha-
nistic schema and with a more integrated analysis of the
available data as a process of evidence-based mechanistic
reasoning [7, 8].
Challenges with vitamin D, ﬁsh oils and vitamin E
The workshop considered two situations that exemplify the
difﬁculties of performing nutritional assessment in which
assessments would probably beneﬁt from more information
of the bases of the available observations. In the ﬁrst
instance, vitamin D is well known for increasing calcium
absorption and enhancing bone health. Substantial epide-
miological evidence and signiﬁcant clinical trial data sug-
gest that vitamin D intake can have important effects on the
risk of falls, cancer, cardiovascular disease and other health
effects. Given the available evidence today summarized in
several meta-analyses, vitamin D supplementation for fall
prevention should not be delayed as a health claim and
general recommendation among the senior population. This
suggestion is in line with the Agency for Healthcare
Research and Quality (AHRQ) for the US Preventive
Services Task Force [9], the 2010 American Geriatric
Society/British Geriatric Society Clinical Practice Guide-
line [10], the 2010 assessment by the IOF [11], the 2011
endocrine society clinical practice guideline [12], and the
recent opinion by the EFSA [13], all of which identiﬁed
vitamin D as an effective intervention to prevent falling in
older adults.
In contrast, the Institute of Medicine (IOM) report
published in 2010 concluded that the data of vitamin D on
fall prevention is inconclusive [14]. However, the evidence
for vitamin D’s effects on falls has been misinterpreted by
the IOM disregarding the overall beneﬁt across all trials in
their analyses and most subgroups deﬁned by the IOM.
For other non-skeletal endpoints of vitamin D, there
are data from large cohort studies, small clinical trials
and mechanistic studies that support a beneﬁt of higher
25-hydroxyvitamin D concentrations on cardiovascular
health, immunity and cancer prevention (especially colo-
rectal cancer). However, these health beneﬁts have not
been conﬁrmed by large randomized trials, and therefore,
the health claims cannot be substantiated. Notably, how-
ever, lack of large randomized trials does not mean lack of
beneﬁt as suggested by the IOM report [15].
A similar area of difﬁculty is the appraisal of the impact
of ﬁsh oils and vitamin E on human health. Large obser-
vational studies, randomized clinical trials and experi-
mental studies have evaluated the effects of ﬁsh
eicosapentaenoic acid (EPA) and docosahexaenoic acid
(DHA) consumption on fatal coronary heart disease and
sudden cardiac death. These studies provide concordant
evidence that modest consumption of ﬁsh or ﬁsh oil (1–2
servings/week of oily ﬁsh or *250 mg/day of EPA and
DHA) substantially reduces the risk of coronary heart
disease and sudden cardiac death. Pooled analysis of ran-
domized clinical trials and prospective cohort studies
demonstrates a 36% lower risk of coronary heart disease
and 17% lower risk of total mortality comparing 0 and
250 mg/day of EPA and DHA with little additional beneﬁts
with higher intakes. Observational studies utilizing tissue
biomarkers of n-3 fatty acids, the reductions in risk are
even larger. Intake of 250 mg/day of EPA and DHA
appears sufﬁcient for primary prevention. A variety of
seafood should be consumed; individuals with very high
consumption (C5 servings/week) and pregnant and nursing
mothers should consume 2 seafood servings/week, limiting
the intake of species highest in mercury levels. On the basis
of both the strength of the evidence and the potential
magnitude of effect, the beneﬁts of ﬁsh intake exceed the
potential risks. Moderate consumption of ﬁsh and ﬁsh oil
should be among the ﬁrst-choice preventatives for coronary
heart disease and sudden cardiac death.
Although the hypothesis that vitamin E may reduce the
risk of cardiovascular disease and cancer is an intriguing
area of research, it continues to be an unproven hypothesis.
Inconsistent ﬁndings, and some data that indicate the
potential for adverse effects from very high intakes of
vitamin E, suggest that we exercise caution against making
premature recommendations for high intakes of vitamin E.
Recommendations from research need to be addressed and
veriﬁed in multiple studies using a variety of designs. Thus,
the use of health claims on foods presents a problem:
conveying a message in a compact way to be readily
grasped by the lay person and passing a reality check on a
topic not fully supported by available scientiﬁc evidence.
The problem results, of course, from the very deﬁnition of
health, which encompasses acute and chronic, young and
old, prevention and treatment. Disease risk is generally
being looked at on a population basis, not on an individual
basis, and this will probably remain so before signiﬁcant
advances in personalized medicine will have occurred. In
addition to the recognized nutrients, research interests have
focused on protection by ﬂavanol-rich foods against vas-
cular dysfunction and oxidative damage. The recent EFSA
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and level of scientiﬁc evidence required to substantiate
health claims continue to be an issue. Further to this issue,
however, will be the challenges of justifying multiple
beneﬁts from single dietary components or groups of
components or of single beneﬁts derived from multiple
dietary components. Both these scenarios are important in
the context of health but as yet the justiﬁcation of these as
with water-soluble tomato components [16].
Nutraceuticals, supplements and claims
Dietary supplements (term used by US FDA), food sup-
plements (term used in Europe) or nutraceuticals (termi-
nology of Health Canada) show speciﬁc nutritional value
and/or provide speciﬁc healthy or body function effects.
The characteristic values of such food products are deﬁned
and promoted by food or health claims. Due to their origin
and long-term use, nutraceuticals are considered safe. Their
claims have to be justiﬁed by portions ingested in the
product and scientiﬁcally proven in a target population.
The claim must be understandable by the consumers. Such
products, especially when deﬁned by health claims, are
positioned between ordinary food and drugs (medicinal
products); they are intended to strengthen or protect the
healthy state. The market for these products is attractive
and rapidly growing. National regulations are often not
consistent, thereby hindering internationally harmonized
market access on levels of notiﬁcation or speciﬁc
regulations.
EFSA evaluates and harmonizes the health claims from
the European Union (EU) Member States as a scientiﬁc
adviser to the European Commission (EC). These state-
ments are used for approval and market access according to
the deﬁned categories of products and claims, which ﬁnally
also determine the product declaration.
Supplements have some peculiarities that inﬂuence the
scientiﬁc approach and proof of efﬁcacy. Neglecting such
aspects may result in conﬂicting study results and, there-
fore, require careful consideration for evaluation and use
[17, 18]. EFSA has done a large volume of work to har-
monize and consolidate requested 44,000 claims to actually
about 2,800 (80% denied). Most are classiﬁed in generally
accepted functional claims (article 13.1) and nutrition
claims according to a positive list. Few innovative claims
(article 13.5) or risk reduction and children’s health claims
(article 14) have been approved because of the heavy
burden for scientiﬁc proof and a clear product–effect
relationship (causality), although some have been approved
[13].
Even so, the EFSA NDA panel’s decisions are often
considered difﬁcult to understand and to interpret.
Furthermore, there are concerns about the transparency and
consistency of the evaluation procedures: The absence of a
clear template for evaluations and reports increases these
concerns.
If the scientiﬁc assessment statements of EFSA do not
provide an appropriate and transparent assessment of cau-
sal inference, then legal disputes are inevitable [19]. There
is a clear need to improve the guidance and exchange with
all relevant stakeholders to sustain and develop the
potential of safe and effective supplements to play a cost-
efﬁcient role for health maintenance in consumers at risk
[20].
Nutrient reference values and public understanding
of nutrition
Nutrient reference values are expected to inform and edu-
cate consumers, and their content and effectiveness in
achieving this were reviewed. Codex established the
Guidelines on Nutrition Labelling in 1985, indicating that
numerical information on vitamins and minerals should be
expressed in metric unit and/or as a percentage of the
nutrient reference values (NRVs). The Codex Guidelines
for Vitamin and Mineral Food Supplements (CAC/GL
55-2005) [21] and Codex Guidelines for Use of Nutrition
and Health Claims (CAC/GL 23-1997, Rev. 1-2004) [22]
also indicate the NRVs as a basis for expressing nutrient
content and for criteria of nutrition and health claims in
food labelling. Following the recommendations of 1988
Helsinki Expert Consultation, a single set of NRVs cur-
rently in use was set in 1993 for nine vitamins (A, D, C,
thiamine, riboﬂavin, niacin, B6, folic acid/folate and B12)
and ﬁve minerals (Ca, Mg, Fe, Zn and I). In 2004, the
Codex Committee on Nutrition and Foods for Special
Dietary Uses (CCNFSDU) agreed to add and update the
current Codex NRVs for vitamins and minerals. This is
particularly important because reference nutrient intake
values have been expanded into multiple categories since
the mid-1990s, most notably the average requirement (AR)
and individual nutrient level, at 98th percentile (INL98).
Therefore, the major concerns in this revision were to
determine which category of these reference nutrient intake
values should be used as the basis for nutrition labelling
and which age groups should be considered for use
consistently throughout the labelling process to provide
consumers with simple, coherent, understandable and
meaningful reference points. The CCNFSDU has devel-
oped principles for the ﬁrst stage of the process. The INL98
was considered to be the preferable measure because, by
deﬁnition, it meets the requirements of practically all who
will be using the label in the population. Regarding age
groups, CCNFSDU considered that a weighted approach
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groups above 36 months throughout the life cycle would be
impractical at the international level. As the major pro-
portion of the population in most countries is adults, the
CCNFSDU selected a simple arithmetic mean of adult
males and females in the age range 19–65 years for males
and 19–50 years for premenopausal females excluding
pregnancy and lactation, consistent with the age ranges
published by World Heath Organization/Food and Agri-
culture Organization (WHO/FAO). One of the most difﬁ-
cult challenges for the manufacturer and the regulator is to
anticipate how the NRVs and other information on labels
will be understood and utilized by the consumer. Conse-
quently, in the absence of data from appropriately designed
studies, there is much disagreement about how the con-
sumer will use the information on the label. Further, in this
vacuum, regulatory and policy authorities around the world
have taken many different approaches to the development
of related policy. A worthwhile goal for industry and reg-
ulatory authorities should be the reduction of reducing the
label information asymmetry from one country to
another—especially in Europe under the EU and among all
countries in order to facilitate trade. Despite an abundance
of research in this area, no consensus as to the optimal
labelling system has yet developed.
A global legislative perspective: WTO and Codex
Alimentarius
In maintaining and developing its market, the food sup-
plement industry, assuming the cooperation of a sponsoring
government, can use the WTO international trade rules as
part of advocacy efforts or in formal dispute settlement to
address regulatory hurdles affecting their business. Legal
arguments against two particular regulatory initiatives have
been developed and are available.
First, regulatory measures which restrict the sale of vita-
minandmineralfoodsupplementsbyestablishingmaximum
levels of nutrient content based solely on recommended
dietary allowances (RDA) appear to violate WTO rules,
because they (1) are not based on a risk assessment nor
sufﬁcient scientiﬁc evidence, (2) are more burdensome than
standards applicable to producers of comparable products
such as certain conventional foods, and (3) exceed the level
of protection of a relevant international (Codex) standard
without scientiﬁc justiﬁcation. In addition, it can be argued
that such regulatory restrictions are more trade-restrictive
than necessary and have the effect of creating unnecessary
obstaclestointernationaltrade,becauselesstrade-restrictive
alternatives (e.g. labelling with maximum intake informa-
tion combined with higher maximum nutrient levels based
on a risk assessment) are available.
Second, EFSA and the European Commission’s applica-
tionoftheEUNutritionandHealthClaimsRegulationmaybe
overly restrictive in violation of WTO rules. If the European
Commission acts upon the EFSA’s negative opinions on
almost all health claims relating to food supplements not
containing vitamins or minerals, it can be argued that the
regulation and its conformity assessment procedures as
applied are moretrade-restrictive thannecessary and resultin
an unnecessary obstacle to international trade, in particular
because the EFSA (1) consistently failed to take into account
and weigh the totality of the available evidence, (2) applied
drug-likestandardstoclaimsforfoodproducts,and(3)didnot
apply different standards to different claims, but instead
subjected all claims to the highest standard. The trade-
restrictiveimpactoftheEFSA’sapproachwillbesevereifthe
EC acts upon its opinions, while a less trade-restrictive
approach (e.g. weighing all the evidence and taking into
account the end-use and nature of the claims and products)
would not lead to signiﬁcant risks for consumers.
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